Stock CLN CELON PHARMA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Pharmaceuticals

Market Closed - Warsaw S.E.
Other stock markets
 16:55:43 27/06/2024 BST 		5-day change 1st Jan Change
15.68 PLN 0.00% Intraday chart for Celon Pharma S.A. -0.88% +1.42%
06-17 Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl? 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra) CI
05-22 Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,786 1,825 1,691 715.5 789.3 800.6 - -
Enterprise Value (EV) 1 1,720 1,781 1,558 659.4 687.6 776 786.5 800.6
P/E ratio 147 x 84.5 x -133 x -18.2 x -28.1 x -38.2 x 188 x -131 x
Yield 0.2% 0.17% - 2.07% 0.58% 0.6% 0.6% 0.57%
Capitalization / Revenue 17.5 x 13.1 x 8.49 x 3.68 x 3.64 x 3.45 x 2.87 x 2.7 x
EV / Revenue 16.8 x 12.8 x 7.82 x 3.39 x 3.18 x 3.34 x 2.82 x 2.7 x
EV / EBITDA 60.5 x 32.5 x 50.4 x 97.6 x 30.2 x 16.9 x 14.9 x 12.6 x
EV / FCF -24.6 x -63 x 599 x 22.6 x -16.7 x 43.9 x 34.9 x 19.7 x
FCF Yield -4.07% -1.59% 0.17% 4.43% -5.98% 2.28% 2.87% 5.09%
Price to Book 4.01 x 4.2 x - 1.49 x 1.77 x 1.91 x 1.93 x 2.04 x
Nbr of stocks (in thousands) 45,000 45,000 51,000 51,035 51,057 51,056 - -
Reference price 2 39.70 40.55 33.15 14.02 15.46 15.68 15.68 15.68
Announcement Date 19/03/20 31/03/21 02/05/22 26/04/23 24/04/24 - - -
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 102.2 139.3 199.1 194.6 216.6 232 278.7 296.4
EBITDA 1 28.43 54.76 30.89 6.759 22.77 46 52.85 63.5
EBIT 1 6.898 23.88 -10.45 -37.34 -27.24 -5 3.555 12.03
Operating Margin 6.75% 17.14% -5.25% -19.19% -12.58% -2.16% 1.28% 4.06%
Earnings before Tax (EBT) 1 7.809 22.07 -15.09 -36.45 -19.97 -5 5.623 15.4
Net income 1 11.93 21.49 -11.61 -39.28 -28.12 -5 3.328 12.55
Net margin 11.67% 15.43% -5.83% -20.18% -12.99% -2.16% 1.19% 4.23%
EPS 2 0.2700 0.4800 -0.2500 -0.7700 -0.5500 -0.4100 0.0833 -0.1200
Free Cash Flow 1 -70 -28.26 2.6 29.2 -41.13 17.67 22.53 40.73
FCF margin -68.46% -20.29% 1.31% 15.01% -18.99% 7.61% 8.09% 13.74%
FCF Conversion (EBITDA) - - 8.42% 432.09% - 38.41% 42.64% 64.15%
FCF Conversion (Net income) - - - - - - 677.18% 324.57%
Dividend per Share 2 0.0800 0.0700 - 0.2900 0.0900 0.0933 0.0933 0.0900
Announcement Date 19/03/20 31/03/21 02/05/22 26/04/23 24/04/24 - - -
1PLN in Million2PLN
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 52.92 41.94 52.83 45.04 149.6 43.89 68.95 48.84 54.88 40.33 65.5 62.5 64.3
EBITDA 1 - 0.551 3.136 0.146 -16.55 -1.839 23.1 2.986 3.508 -5.151 6.9 5.8 6.4
EBIT -5.992 -11.1 -8.382 -11.56 -25.78 -13.61 11.42 -9.768 -9.276 -17.88 - - -
Operating Margin -11.32% -26.46% -15.87% -25.67% -17.24% -31.01% 16.56% -20% -16.9% -44.33% - - -
Earnings before Tax (EBT) -7.113 - -8.529 -11.4 -25.04 - - - - -12.86 - - -
Net income -4.079 -7.512 -8.11 -11.67 -27.61 -9.475 9.143 -6.815 -14.97 -15.67 - - -
Net margin -7.71% -17.91% -15.35% -25.91% -18.46% -21.59% 13.26% -13.95% -27.27% -38.85% - - -
EPS -0.1000 - -0.0100 -0.0100 - - - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 02/05/22 25/05/22 28/09/22 23/11/22 26/04/23 24/05/23 20/09/23 22/11/23 24/04/24 22/05/24 - - -
1PLN in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 66.7 44 133 56.1 102 24.6 14.1 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -70 -28.3 2.6 29.2 -41.1 17.7 22.5 40.7
ROE (net income / shareholders' equity) 2.67% 4.89% -2.58% -7.6% -6.08% -1% 2.75% -
ROA (Net income/ Total Assets) 2.07% - - - - - - -
Assets 1 577.5 - - - - - - -
Book Value Per Share 2 9.890 9.660 - 9.400 8.730 8.230 8.110 7.680
Cash Flow per Share - - - - - - - -
Capex 1 65 99.2 41.4 31.5 32.8 33.7 37.7 45.1
Capex / Sales 63.52% 71.2% 20.77% 16.17% 15.15% 14.53% 13.53% 15.2%
Announcement Date 19/03/20 31/03/21 02/05/22 26/04/23 24/04/24 - - -
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Celon Pharma S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
15.68 PLN
Average target price
16.78 PLN
Spread / Average Target
+7.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CELON PHARMA S.A. Stock Celon Pharma S.A.
+1.42% 198M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.95% 811B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.62% 640B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.98% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.08% 333B
ABBVIE INC. Stock AbbVie Inc.
+9.05% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.30% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+2.41% 225B
NOVARTIS AG Stock Novartis AG
+12.47% 218B
AMGEN INC. Stock Amgen Inc.
+8.91% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CLN Stock
  4. Financials Celon Pharma S.A.